Association between MRI parameters and the MS severity scale: a 12 year follow-up study

Abstract

Background

Several magnetic resonance imaging (MRI) parameters are known to be associated with short-term outcome in multiple sclerosis (MS) patients. MS-related disability typically progresses over decades, stressing the need for longer follow-up studies. Until now, these studies are relatively sparse and, therefore, the predictive value of MRI parameters for clinical disability remains largely unknown.

Objective

To assess the predictive value of brain MRI parameters, which are obtained during the first 3.3 years of the study for overall disease severity as measured by the MS Severity Score (MSSS) after 12.2 years follow-up.

Methods

Forty-six MS patients were included in the study. MRI parameters included both lesion loads and atrophy measures. Average and change parameters were calculated for MRI parameters and subsequently used as independent variables in regression models, while MSSS was the dependent variable.

Results

Follow-up (FU) was obtained in 43/46 patients (94%) and median expanded disability status scale (EDSS) score increased significantly from 2.5 to 4.0. At last FU median MSSS was 4.3 (range 2.2–6.9). In univariate analyses, both change and cross-sectional T1-hypointense lesion load and ventricular atrophy measures were associated with MSSS. A multiple regression model included the change parameter of hypointense T1-lesion load (BHLL). This model explained 20% of variance in MSSS, which increased to 34% when type of disease (relapsing remitting or secondary progressive), age, and sex were entered additionally.

Conclusion

MRI measures of axonal loss are associated with higher overall disease severity in MS patients.

Keywords

disability longitudinal MRI multiple sclerosis prognosis

Get full access to this article

View all access options for this article.

References

1 Confavreux C Vukusic S Adeleine P . Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126: 770–782.

2 Myhr KM Riise T Vedeler C . Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler 2001; 7: 59–65.

3 Runmarker B Andersen O . Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993; 116(pt 1): 117–134.

4 Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.

5 Weinshenker BG . The natural history of multiple sclerosis. Neurol Clin 1995; 13: 119–146.

6 McDonald WI Compston A Edan G . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.

7 Korteweg T Tintore M Uitdehaag B . MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol 2006; 5: 221–227.

8 Fisniku LK Brex PA Altmann DR . Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131: 808–817.

9 Minneboo A Barkhof F Polman CH Uitdehaag BM Knol DL Castelijns JA . Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol 2004; 61: 217–221.

10.

10 Filippi M Horsfield MA Tofts PS Barkhof F Thompson AJ Miller DH . Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain 1995; 118(pt 6): 1601–1612.

11.

11 Miller DH Grossman RI Reingold SC McFarland HF . The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998; 121(pt 1): 3–24.

12.

12 van Walderveen MA Kamphorst W Scheltens P . Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998; 50: 1282–1288.

13.

13 Paolillo A Pozzilli C Giugni E . A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta. Eur J Neurol 2002; 9: 645–655.

14.

14 Sailer M Losseff NA Wang L Gawne-Cain ML Thompson AJ Miller DH . T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow-up study. Eur J Neurol 2001; 8: 37–42.

15.

15 Truyen L van Waesberghe JH van Walderveen MA . Accumulation of hypointense lesions (“black holes”) on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996; 47: 1469–1476.

16.

16 Fisher E Rudick RA Simon JH . Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412–1420.

17.

17 Bermel RA Sharma J Tjoa CW Puli SR Bakshi R . A semiautomated measure of whole-brain atrophy in multiple sclerosis. J Neurol Sci 2003; 208: 57–65.

18.

18 Dastidar P Heinonen T Lehtimaki T . Volumes of brain atrophy and plaques correlated with neurological disability in secondary progressive multiple sclerosis. J Neurol Sci 1999; 165: 36–42.

19.

19 Losseff NA Wang L Lai HM . Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996; 119: 2009–2019.

20.

20 Brex PA Ciccarelli O O’Riordan JI Sailer M Thompson AJ Miller DH . A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158–164.

21.

21 Rudick, RA, Lee, JC, Simon, J, Fisher, E. Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study. Ann Neurol 2006; 60: 236–242.

22.

22 Poser CM Paty DW Scheinberg L . New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227–231.

23.

23 Lublin FD Reingold SC . Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907–911.

24.

24 Lechner-Scott J Kappos L Hofman M . Can the Expanded Disability Status Scale be assessed by telephone? Mult Scler 2003; 9: 154–159.

25.

25 Roxburgh RH Seaman SR Masterman T . Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144–1151.

26.

26 Kalkers NF Ameziane N Bot JC Minneboo A Polman CH Barkhof F . Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol 2002; 59: 1572–1576.

27.

27 Bielekova B Kadom N Fisher E . MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology 2005; 65: 1071–1076.

28.

28 van Waesberghe JH Kamphorst W De Groot CJ . Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999; 46: 747–754.

29.

29 van Walderveen MA Barkhof F Hommes OR . Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology 1995; 45: 1684–1690.

30.

30 Kalkers NF Vrenken H Uitdehaag BM Polman CH Barkhof F . Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue. Mult Scler 2002; 8: 410–414.

31.

31 Paolillo A Pozzilli C Gasperini C . Brain atrophy in relapsing-remitting multiple sclerosis: relationship with ‘black holes’, disease duration and clinical disability. J Neurol Sci 2000; 174: 85–91.

32.

32 Dalton CM Brex PA Jenkins R . Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 73: 141–147.

33.

33 Dalton CM Miszkiel KA O’Connor PW Plant GT Rice GP Miller DH . Ventricular enlargement in MS: one-year change at various stages of disease. Neurology 2006; 66: 693–698.

34.

34 Hobart J Freeman J Thompson A . Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain 2000; 123(pt 5): 1027–1040.

35.

35 Whitaker JN McFarland HF Rudge P Reingold SC . Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler 1995; 1: 37–47.

36.

36 Kappos L Traboulsee A Constantinescu C . Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006; 67: 944–953.